-
bluebird bio Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 328
-
Executives
- Daniel Lynch
- Nick Leschly
- Jeffrey Walsh
- Susanna High
- Philip Gregory
- David Davidson
- Jason Cole
- John Agwunobi
- Mary Hedley
- Douglas Melton
-
Company address
- 150 Second Street
- Cambridge, MA 02141
- United States of America
- 1-339-499-9300
-
Investor Relation Site
Link
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington. Its product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ss-thalassemia, and severe sickle cell disease. The company’s lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor (TCR) product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts
bluebird bio Inc: Slide deck